Study of MRA in Patients With Rheumatoid Arthritis (RA)

An Open-label, Extension, Phase II Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With RA Who Were Participated in Study MRA009JP

This is an open-label, extension, Phase II study to evaluate the long-term safety and efficacy of MRA in Patients with RA who were participated in Study MRA009JP.

Inclusion Criteria:

• Patients administered MRA more than 2 times in preceding study, MRA009JP, and evaluated the efficacy and the safety.
• Patients confirmed to have shown the safety in the preceding study.

Exclusion Criteria:

• Patients with Class IV Steinbrocker functional activity at evaluation within 4 weeks before treatment with the study drug

• Patients who received any of the following treatments between the start of preceding study and the registration of this study.

  1. Plasma exchange therapy
  2. Surgical treatment (e.g., operation)